Success Metrics

Active Trials
2(50%)

Phase Distribution

Ph phase_2
3
75%
Ph not_applicable
1
25%

Phase Distribution

0

Early Stage

3

Mid Stage

0

Late Stage

Phase Distribution4 total trials
Phase 2Efficacy & side effects
3(75.0%)
N/ANon-phased studies
1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

2

trials recruiting

Total Trials

4

all time

Status Distribution
Active(4)

Detailed Status

Not yet recruiting2
Recruiting2

Development Timeline

Analytics

Development Status

Total Trials
4
Active
2
Success Rate
N/A
Most Advanced
Phase 2

Trials by Phase

Phase 23 (75.0%)
N/A1 (25.0%)

Trials by Status

not_yet_recruiting250%
recruiting250%

Recent Activity

2 active trials
Showing 4 of 4
recruitingnot_applicable

ctDNA-driven Adaptive Proton Craniospinal Irradiation in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis After Resistance to Third-Generation TKIs in the Consolidation Phase

NCT07751536
not_yet_recruitingphase_2

Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges Metastatic

NCT06497543
recruitingphase_2

Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases

NCT06440954
not_yet_recruitingphase_2

Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI

NCT06441045

Clinical Trials (4)

Showing 4 of 4 trials
NCT07751536Not Applicable

ctDNA-driven Adaptive Proton Craniospinal Irradiation in Non-Small Cell Lung Cancer With Leptomeningeal Metastasis After Resistance to Third-Generation TKIs in the Consolidation Phase

Recruiting
NCT06497543Phase 2

Intrathecal Pemetrexed for SCLC Patients With Refractory Brain Metastases or Leptomeninges Metastatic

Not Yet Recruiting
NCT06440954Phase 2

Efficacy and Resistance Mechanisms of IP in NSCLC With Leptomeningeal Metastases

Recruiting
NCT06441045Phase 2

Double Dose of Third-generation EGFR-TKI Plus Intrathecal Pemetrexed Versus Double Dose of Third-generation EGFR-TKI in Patients With LM Progression Following the Treatment of Routine Dose of Third-generation EGFR-TKI

Not Yet Recruiting

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4